Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Diffusion MRI outlined viable tumour volume beats GTV in intra-treatment stratification of outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Diabetes increases the risk of serious adverse events after re-irradiation of the spine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Hanna Rahbek Mortensen
  • Jens Overgaard
  • Lena Specht
  • Marie Overgaard
  • Jørgen Bjerregaard Johansen
  • Jan F Evensen
  • Lisbeth Juel Andersen
  • Elo Andersen
  • Cai Grau
Vis graf over relationer
BACKGROUND AND PURPOSE: The aim of this report was to describe the incidence and prevalence of acute and late morbidity in the DAHANCA 6&7 multicentre randomised trial with accelerated radiotherapy for squamous cell carcinoma of the head and neck. MATERIALS AND METHODS: The DAHANCA 6&7 study included 1476 patients eligible for primary radiotherapy alone. Patients were randomised between five or six weekly fractions of conventional radiotherapy. The prescribed dose was 66-68Gy in 33-34 fractions. All patients were seen weekly during treatment and at regular intervals after completion where detailed morbidity recording was done. Reports from 1468 patients were available for analysis of treatment related morbidity. RESULTS: Accelerated radiotherapy caused a significant (p
OriginalsprogEngelsk
TidsskriftRadiotherapy & Oncology
Vol/bind103
Udgave nummer1
Sider (fra-til)69-75
ISSN0167-8140
DOI
StatusUdgivet - 2012

ID: 34758432